Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 17, Issue 6, 1998, Pages 434-440

  Leophonte P ^a   Baldwin, R J T ^b   Pluck, N ^c  

^a CHU RANGUEIL   (France)

^b Oak Street Surgery ^*  (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CLAVULANIC ACID; TROVAFLOXACIN;

ADULT; AGED; ARTICLE; CHLAMYDOPHILA PNEUMONIAE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIARRHEA; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIAE; VAGINITIS; VERTIGO;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BRONCHITIS; CHLAMYDIA INFECTIONS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HAEMOPHILUS INFECTIONS; HUMANS; MALE; MIDDLE AGED; NAPHTHYRIDINES; PNEUMOCOCCAL INFECTIONS;

EID: 0031783171     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050104     Document Type: Article

References (27)

1. Niederman MS: Acute exacerbations of chronic bronchitis: the role of infection and the selection of appropriate therapy. Pulmonary and Critical Care Update (1996) 11:2-7
2. Ball P, Harris JM, Lowson D, Tillotson G, Wilson R: Acute infective exacerbations of chronic bronchitis. Quarterly Journal of Medicine (1995) 88:61-68
3. Chodosh S: Treatment of chronic bronchitis: state of the art. American Journal of Medicine (1991) 91, Supplement 6A: 87-92
4. Fagon J-Y, Chastre J, Trouillet J-L, Domart Y, Dombret M-C, Bornet M, Gibert C: Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis: use of the protected specimen brush technique in 54 mechanically ventilated patients. American Reviews of Respiratory Disease (1990) 142:1004-1008
5. Smith CB, Golden C, Klauber MR, Kanner R, Renzetti A: Interactions between viruses and bacteria in patients with chronic bronchitis. Journal of Infectious Disease (1976) 134:552-561
6. Wilson R: Outcome predictors in bronchitis. Chest (1995) 108:53-57
7. Saint S, Bent S, Vittinghoff E, Grady D: Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. Journal of the American Medical Association (1975) 273:957-960
8. Pérez-Gonzalvo ME, Mosquera-Pestaña JA, Ramos D, Apilánez J, Borja J, Arnau C, García-Barbal J, Marín-Pardo J, on behalf of the Study of Ofloxacin in Lower Respiratory Tract Infections Research Group: Ofloxacin versus trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbation of chronic bronchitis. Clinical Therapeutics (1996) 18:440-447
9. Cazzola M, Vinciguerra A, Beghi GF, Paizis G, Giura R, Madonini V, Fiorentini F, Consigli GF, Tonna M, Casalini A: Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. Journal of Chemotherapy (1995) 7:432-441
10. Polubiec A, Jorasz I, Pietrzak J, Soszka A, Stepka K, Zaryn A: A randomized study comparing low-dose ciprofloxacin and ofloxacin in the treatment of lower respiratory tract infections. Infection (1994) 22:62-64
11. Pechère J-C, Gootz TD: Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens. European Journal of Clinical Microbiology & Infectious Diseases (1998) 17:405-412
12. Hendershot EF: Fluoroquinolones. Infectious Disease Clinics of North America (1995) 9:715-730
13. Cockburn J, Gibberd RW, Reid AL, Sanson-Fisher RW: Determinants of non-compliance with short term antibiotic regimens. British Medical Journal (1987) 295:814-818
14. Neu HC, Chin N-X: In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy (1994) 38:2615-2622
15. Kenny GE, Cartwright FD: Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrobial Agents and Chemotherapy (1996) 40:1048-1049
16. Child J, Andrews J, Boswell F, Brenwald N, Wise R: The in-vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. Journal of Antimicrobial Chemotherapy (1995) 35:869-876
17. Teng R, Liston TE, Harris SC: Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy (1996) 37:955-963
18. Andrews JM, Honeybourne D, Brenwald NP, Bannerjee D, Iredale M, Cunningham D, Wise R: Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B: 797-802
19. Behler PG, Boge K, Bohning W, Gams W, Gartner-Toth M, Wettengel R: Amoxicillin/clavulanic acid vs cefetamet pivoxil in the treatment of acute exacerbation of chronic bronchitis (AECB) in adults. Journal of Chemotherapy (1995) 7, Supplement 1:16-20
20. Periti P, Novelli A, Schildwachter G, Schmidt-Gayk H, Ryo Y, Zuck P: Efficacy and tolerance of cefpodoxime proxetil compared with co-amoxiclav in the treatment of exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy (1990) 26, Supplement E:63-69
21. Rademaker CM, Sips AP, Beumer HM, Hoepelman IM, Overbeek BP, Mollers MJ, Rozenberg-Arska M, Verhoef J: A double-blind comparison of low-dose ofloxacin and amoxicillin/clavulanic acid in acute exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy (1990) 26, Supplement D:75-81
22. Allegra L, Komnietzko N, Leophonte PJ, Pauwels R, Guyen JM, Petitpretz P: Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study. Journal of Antimicrobial Chemotherapy (1996) 37, Supplement A:93-104
23. Doern GV: Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. American Journal of Medicine (1995) 99, Supplement 6B:3-7
24. Sefton AM, Maskell JP, Seymour AC, Minassian M, Williams JD: Comparative in-vitro activity of CP-99219, a new quinolone, against respiratory pathogens. Journal of Antimicrobial Chemotherapy (1996) 37:803-808
25. Batty KT, Davis TM, Ilett KF, Dusci LJ, Langton SP: The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. British Journal of Clinical Pharmacology (1995) 39:305-311
26. Vincent J, Teng R, Dogolo LC, Willavize SA, Friedman HL: Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B: 81-86
27. Trémolières F, de Kock F, Pluck N, Daniel R: Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia: results of a multicentre, double-blind study. European Journal of Clinical Microbiology & Infectious Diseases (1998) 17:447-453